A parallel, randomised, double blind, placebo controlled study to investigate the effect of SagaPro on nocturia in men

Registry ID

EUCTR2010-019668-35

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

SagaMedica ehf.

Start date

2010-05-05

Completion date

2011-02-11

Last update

2026-08-16

Conditions

• Nocturia

Summary

The primary study objective is to assess the effect of SagaPro compared with placebo, given once daily in the evening, in reducing bothersome LUTS, especially nocturia, often associated in men with BPH.

Locations

• , , Iceland

Related clinical trials

• Multi-center Trial to Improve Nocturia and Sleep in Older Adults
• A Community-based Solution for Nocturia: Integrating Digital Technology and Behavioral Interventions
• A Pilot Study to Evaluate PureWick for Nocturia
• Moxibustion for Nocturia
• Safety and Performance of UCon Bar Electrode for the Treatment of Overactive Bladder (OAB) and Bowel Dysfunction (BD)
• APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women

View on source registry